New York Health Care Inc. (BBAL) Financials Nov 3, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
New York Health Care Inc. (BBAL) Financials Nov 3, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for New York Health Care Inc.


Fiscal year is January-December. All values USD millions. 2003 2004 2005 2006 2007 5-year trend
Sales/Revenue 45.06M 42.29M 44.72M 45.56M 44.4M
Cost of Goods Sold (COGS) incl. D&A 36.71M 35.6M 37.73M 37.42M 37.03M
COGS excluding D&A 36.11M 34.78M 37.08M 36.75M 36.63M
Depreciation & Amortization Expense 606,747 819,887 652,152 672,584 404,622
Depreciation 129,718 50,389 50,002 52,523 40,000
Amortization of Intangibles 477,029 769,498 602,150 620,061 364,622
Gross Income 8.35M 6.69M 6.99M 8.14M 7.37M
2003 2004 2005 2006 2007 5-year trend
SG&A Expense 12.54M 11.17M 16.08M 11M 7.8M
Research & Development 1.24M 1.06M 2.8M 1.64M 648,759
Other SG&A 11.3M 10.12M 13.28M 9.36M 7.15M
Other Operating Expense 0 0 0 0 0
Unusual Expense 17.87M 1.74M 0 926,322 788,632
EBIT after Unusual Expense (17.87M) (1.74M) 0 (926,322) (788,632)
Non Operating Income/Expense 0 0 0 0 193,815
Non-Operating Interest Income 51,255 69,877 89,108 164,969 77,893
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 2,173 29,538 24,135 61,394 29,066
Gross Interest Expense 2,173 29,538 24,135 61,394 29,066
Interest Capitalized 0 0 0 0 0
Pretax Income (22.01M) (6.19M) (9.03M) (3.68M) (977,724)
Income Tax 39,000 (67,176) 78,628 75,120 74,627
Income Tax - Current Domestic 39,000 (67,176) 78,628 75,120 -
Income Tax - Current Foreign 0 - - 0 0
Income Tax - Deferred Domestic 0 - - 0 0
Income Tax - Deferred Foreign 0 - - 0 0
Income Tax Credits 0 - - 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (22.05M) (6.12M) (9.1M) (3.76M) (1.05M)
Minority Interest Expense 0 0 0 0 0
Net Income (22.05M) (6.12M) (9.1M) (3.76M) (1.05M)
Extraordinaries & Discontinued Operations 0 48,968 2.78M 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 2.78M 0 0
Cumulative Effect - Accounting Chg 0 - - 0 0
Discontinued Operations 0 48,968 - 0 0
Net Income After Extraordinaries (22.05M) (6.07M) (6.32M) (3.76M) (1.05M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (22.05M) (6.12M) (9.1M) (3.76M) (1.05M)
EPS (Basic) (0.91) (0.24) (0.29) (0.11) (0.03)
Basic Shares Outstanding 24.28M 24.94M 31.9M 33.25M 33.54M
EPS (Diluted) (0.91) (0.24) (0.29) (0.11) (0.03)
Diluted Shares Outstanding 24.28M 24.94M 31.9M 33.25M 33.54M
EBITDA (3.59M) (3.67M) (8.44M) (2.19M) (27,112)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 29

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 28

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 24

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 35

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 30

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 20

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Endava Investors: Legal Action Could Recover Your Losses

Updated Category News Views 87

Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...

Continue Reading
New Mortgage Ratings Assigned to Deephaven Trust Portfolio

Updated Category News Views 177

Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...

Continue Reading
Meta Platforms Declares Cash Dividend for Shareholders

Updated Category News Views 325

Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...

Continue Reading
Campine Expects Strong Financial Upsurge in 2024 Performance

Updated Category News Views 125

Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...

Continue Reading
Thumzup Media's Strategic Investment in Dogecoin Ahead of ETFs

Updated Category News Views 147

Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...

Continue Reading